| Identification | More | [Name]
Ethyl (R)-(-)-4-cyano-3-hydroxybutyate | [CAS]
141942-85-0 | [Synonyms]
ATS-5
BUTANOIC ACID, 4-CYANO-3-HYDROXY-, ETHYL ESTER, (R)
BUTANOIC ACID 4-CYANO-3-HYDROXY-ETHYL ESTER, (S)
ETHYL (3R)-4-CYANO-3-HYDROXY-BUTANOATE
ETHYL (R)-4-CYANO-3-HYDROXYBUTANOATE
ETHYL-(R)-(+)-4-CYANO-3-HYDROXYBUTANOATE
Ethyl (R)-(-)-4-cyano-3-hydroxybutyate
ETHYL (R)-(-)-4-CYANO-3-HYDROXYBUTYRATE
ETHYL (R)-4-CYANO-3-HYDROXYBUTYRATE
ETHYL (S)-4-CYANO-3-HYDROXYBUTANOATE
ETHYL (S)-(+)-4-CYANO-3-HYDROXYBUTYRATE
ETHYL(S)-4-CYANO-3-HYDROXY-BUTYRATE
(R)-(-)-4-CYANO-3-HYDROXYBUTYRIC ACID ETHYL ESTER
(R)-4-CYANO-3-HYDROXYBUTYRIC ACID ETHYL ESTER
(R)-(-)-ETHYL 4-CYANO-3-HYDROXYBUTYRATE
(R)-ETHYL 4-CYANO-3-HYDROXYBUTYRATE
(S)-4-CYANO-3-HYDROXYBUTANOATE ETHYL
(S)-ETHYL-4-CYANO-3-HYDROXYBUTYRATE
(R)-4-Cyano-3-hydroxy butanoate
(R)-4-cyano-3-hydroxybutyric | [EINECS(EC#)]
430-220-6 | [Molecular Formula]
C7H11NO3 | [MDL Number]
MFCD00672878 | [Molecular Weight]
157.17 | [MOL File]
141942-85-0.mol |
| Chemical Properties | Back Directory | [Appearance]
yellow liquid | [alpha ]
-5 º (neat) | [Boiling point ]
270 °C(lit.)
| [density ]
1.114 g/mL at 25 °C(lit.)
| [refractive index ]
n20/D 1.448(lit.)
| [Fp ]
>230 °F
| [storage temp. ]
2-8°C | [solubility ]
Chloroform (Sparingly), DMSO (Slightly), Methanol (Slightly) | [form ]
Liquid | [pka]
13.03±0.20(Predicted) | [color ]
Colorless to yellow | [Specific Gravity]
1.114 | [Optical Rotation]
[α]25/D 5°, neat | [BRN ]
5328715 | [InChIKey]
LOQFROBMBSKWQY-ZCFIWIBFSA-N | [CAS DataBase Reference]
141942-85-0(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
Xi | [Risk Statements ]
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S36:Wear suitable protective clothing . | [WGK Germany ]
1
| [HS Code ]
29269090 |
| Questions And Answer(Q&A) | Back Directory | [Application]
Hydroxyglutaryl coenzyme A (HMG-CoA) reductase inhibitors are a new class of lipid-lowering drugs, and they have a market share of more than 10 billion US dollars in the current pharmaceutical field. They can selectively inhibit the rate-limiting enzyme HMG-CoA reductase in cholesterol synthesis in the liver, reduce liver lipoprotein production, and increase the expression of low-density lipoprotein (LDL) cholesterol receptors, thereby reducing plasma cholesterol levels. They can also significantly reduce very low-density lipoprotein (VLDL) and triglycerides, and increase anti-atherosclerotic high-density protein (HDL), preventing atherosclerosis and coronary heart disease.
Ethyl (R)-(-)-4-cyano-3-hydroxybutyate is an important intermediate for the synthesis of HMG-CoA reductase inhibitors. If it is used as a raw material, synthetic atorvastatin is mainly used for the treatment of hypercholesterolemia and mixed hyperlipidemia, coronary heart disease and stroke.
|
|
|